razoxane has been researched along with Mesothelioma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aldieri, E; Betta, PG; Bosia, A; Doublier, S; Gazzano, E; Ghigo, D; Orecchia, S; Riganti, C | 1 |
| Ash, A; Borden, EC; Enterline, HT; Falkson, G; Laucius, JF; Lerner, H; Paul, AR; Rosenbaum, C | 1 |
| Green, MR; Herndon, JE; Kindler, HL; Kosty, MP; Vogelzang, NJ | 1 |
1 trial(s) available for razoxane and Mesothelioma
| Article | Year |
|---|---|
High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Heart Diseases; Humans; Male; Mesothelioma; Middle Aged; Neutropenia; Razoxane; Thrombocytopenia | 2001 |
2 other study(ies) available for razoxane and Mesothelioma
| Article | Year |
|---|---|
Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1alpha.
Topics: Antineoplastic Agents; Asbestos; Asbestos, Crocidolite; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Iron; Lung; Lung Neoplasms; Mesothelioma; Razoxane | 2008 |
Phase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas.
Topics: Adolescent; Adult; Aged; Bone Neoplasms; Drug Evaluation; Female; Humans; Male; Maytansine; Mesothelioma; Middle Aged; Mitolactol; Osteosarcoma; Oxazines; Piperazines; Prognosis; Random Allocation; Razoxane; Sarcoma; Soft Tissue Neoplasms | 1982 |